A1SN34.SA Ascendis Pharma A/S
- Market cap
- BRL 5.80B
- P/E
- 1.3x
- P/B
- 0.67x
- ROE
- 116.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is A1SN34.SA undervalued?
Graham numberThe Graham number of Ascendis Pharma A/S cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ascendis Pharma A/S fundamental analysis
No fundamental analysis for Ascendis Pharma A/S yet.
Ascendis Pharma A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease produc…
Full company profileAscendis Pharma A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ascendis Pharma A/S annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 10.6M | 13.4M | 6.95M | 7.78M | 51.2M | 267M | 364M | 720M | 1.17B |
| Gross Profit | - | - | 6.95M | 4.26M | 39.0M | 222M | 319M | 625M | 1.08B |
| Operating Income | -155M | -227M | -331M | -452M | -562M | -456M | -279M | -136M | 491M |
| EBITDA | -129M | -210M | -408M | -365M | -529M | -411M | -290M | -114M | 544M |
| Net Income | -130M | -218M | -419M | -384M | -583M | -481M | -378M | -228M | 1.67B |
| EPS | -3.09 | -4.54 | -7.79 | -6.74 | -10 | -8.50 | -6.32 | -3.72 | 25 |
| Balance Sheet | |||||||||
| Total Assets | 319M | 677M | 980M | 1.08B | 1.09B | 826M | 1.18B | 1.30B | 2.29B |
| Total Liabilities | 38.9M | 79.6M | 141M | 201M | 826M | 971M | 1.29B | 1.47B | 850M |
| Shareholders' Equity | 280M | 597M | 839M | 884M | 263M | -146M | -106M | -163M | 1.44B |
| Cash & Short-term Investments | 278M | 598M | 719M | 682M | 735M | 399M | 560M | 616M | 812M |
| Cash Flow | |||||||||
| Operating Cash Flow | -139M | -176M | -272M | -418M | -496M | -467M | -306M | 53.9M | 548M |
| Capital Expenditure | 2.65M | 5.16M | 19.9M | 23.7M | 14.5M | 2.44M | 1.43M | 8.49M | 0.00 |
| Free Cash Flow | -141M | -181M | -293M | -442M | -510M | -470M | -308M | 45.4M | 526M |
| Ratios | |||||||||
| ROE | -46.5% | -36.5% | -50.0% | -43.4% | -221.5% | - | - | - | 116.4% |
| ROA | -40.8% | -32.2% | -42.8% | -35.4% | -53.5% | -58.3% | -32.1% | -17.5% | 73.2% |
| Net Profit Margin | -1,229.5% | -1,630.0% | -6,025.5% | -4,931.6% | -1,139.6% | -180.5% | -104.0% | -31.7% | 142.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ascendis Pharma A/S dividends
Ascendis Pharma A/S has not paid dividends in the last 8 fiscal years.
Who owns Ascendis Pharma A/S
Ownership data of Ascendis Pharma A/S is not available yet.
Ascendis Pharma A/S company profile
- Company name
- Ascendis Pharma A/S
- Ticker
- A1SN34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,189
- Fiscal year end
- December
- Address
- Tuborg Boulevard 12, Hellerup, Denmark, 2900
- Phone
- 45 70 22 22 44
- Website
- ascendispharma.com
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ascendis Pharma A/S management
10- Mr. Jan Moller MikkelsenPresident, CEO, Member of Executive Board & Executive Director · born 1960
- Mr. Scott T. SmithCFO, Executive VP & Member of Executive Board · born 1974
- Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive VP, Chief Administrative Officer & Member of the Executive Board · born 1961
- Mr. Michael Wolff Jensen L.L.M.Executive VP, Chief Legal Officer & Member of the Executive Board · born 1971
- Mr. Mads BodenhoffSenior VP, Head of Finance & Principal Accounting Officer · born 1970
- Mr. Chad FugureVice President of Investor Relations
- Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality · born 1961
- Dr. Kennett Sprogoe Ph.D.Executive VP and Head of Research & Product Development · born 1979
- Mr. Joseph KellyHead of U.S. Commercial of Endocrinology · born 1969
- Mr. Jay Donovan WuExecutive VP & President of Ascendis US · born 1986